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Morquio syndrome type A (mucopolysaccharidosis type IVA,
MPS IVA) is a lysosomal disorder caused by insufficient
N-acetylgalactosamine-6-sulfatase (GALNS) activity. The lysosomal
enzyme GALNS catabolizes the glycosaminoglycans (GAG) keratan
sulfate (KS) and chondroitin 6-sulfate (C6S), and deficient GALNS
activity causes accumulation of KS and C6S. While demonstration of
deficient GALNS enzyme activity is the gold standard for diagnosis of
Morquio syndrome type A, detection of elevated urinary GAG (GAG)
levels is often used to screen for Morquio syndrome type A.
However, standard dye-based analyses of total GAG levels (the
quantitative GAG test) have a high false negative rate in the
identification of patients with Morquio syndrome type A, in some
cases leading to misdiagnoses. False positives are also possible. To
address the use of the liquid chromatography-tandem mass spec-
trometry (LC-MS/MS)-based urine KS (uKS) test as an improved
method to measure KS in comparison with dye-based methods, two
international data steering committees were organized by BioMarin
Pharmaceutical Inc. (Nashville, USA and Bahia, Brazil) in 2014. Case
data on age-specific reference ranges for uKS levels in unaffected
individuals and patients with Morquio syndrome type A were
accumulated and the performance of the dye-based GAG test and
LC-MS/MS uKS tests in identifying patients with Morquio syn-
drome type A were compared. Multiple independent international
labs assessed uKS levels by the dye-based GAG test and the LC-MS/
MS uKS test in unaffected individuals and patients with Morquio
syndrome type A. We confirm previous findings that the levels of
uKS decrease with age in unaffected individuals. In particular,
creatinine-normalized uKS levels are highest in children less than
1 year of age and then decrease rapidly. While results from the
dye-based test and the LC-MS/MS uKS test were linearly correlated,
we highlight multiple cases where the superior sensitivity of the
LC-MS/MS uKS test resulted in identification of patients with
Morquio syndrome type A while the dye-based test did not.
Although uKS has, to date, not been shown to be an efficacy
biomarker for enzyme replacement therapy, it is an excellent
screening biomarker for Morquio syndrome type A and potentially
for other disorders. In contrast to dye-based methods, the LC-MS/
MS-based uKS test provides a highly sensitive, specific, and
quantitative measure of elevated KS. Optimally, LC-MS/MS-based
GAG measurements will enable more accurate urine screening for
MPS disorders.
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Mucopolysaccharidosis (MPS) VII is associated with severe
musculoskeletal manifestations, which are particularly prevalent in
the spine. Vertebral dysplasia and accelerated intervertebral disc
degeneration lead to kyphoscoliosis and spinal cord compression,
directly impacting patient mortality and quality of life. A defining
feature of spine disease in MPS VII is the presence of cartilaginous
lesions in the vertebral bodies, indicative of failed cartilage-to-bone
conversion during postnatal development [1,2]; however, the
underlying molecular mechanisms are poorly understood. During
normal vertebral bone formation, cartilaginous rudiments form a
template where resident chondrocytes undergo distinct stages of
differentiation (resting, proliferative, hypertrophic, terminal) regu-
lated by a highly orchestrated pattern of growth factor signaling,
culminating in ossification by osteoblasts. Glycosaminoglycans
(GAG) perform critical roles in regulating the activity of these
growth factors. We hypothesize that abnormal GAG accumulation in
MPS VII disrupts chondrocyte differentiation by interfering with
growth factor signaling, thus preventing normal cartilage-to-bone
conversion. Our objectives were to: 1) identify the earliest develop-
mental age where altered bone formation is evident in MPS VII, and
2) establish the stage at which epiphyseal chondrocyte differentia-
tion is impaired, using the naturally-occurring MPS VII canine model.
We collected thoracic vertebrae from 9 day (n = 2) and 14 day old
(n = 5) litter-matched heterozygote and affected dogs for quantita-
tive PCR and micro-computed tomography (microCT) analyses. This
age range was selected based on previous radiographic, longitudinal
studies of vertebral bone formation in MPS VII dogs [2]. Comparison
of mRNA expression of chondrocyte differentiation (SOX9, RUNX2,
COL10A1) and osteoblast (ALPL, BGLAP) markers, and microCT
visualization of vertebral bodies of heterozygote and MPS VII affected
dogs showed striking differences in bone formation (*, figure) at
14 days whereas at 9 days, no significant differences besides a trend
towards lower RUNX2 expression were detected (Figure). Interest-
ingly, SOX9 expression was downregulated at 14 days for both
heterozygote and affected dogs suggesting that both chondrocyte
populations receive regulatory signals for proliferation but that MPS
VII chondrocytes fail to progress into hypertrophy. Furthermore,
bone volume fraction and bone mineral density quantification of the
vertebral bone primary ossification centers showed no differences
between heterozygote and affected dogs suggesting that at this time
point, the most affected developmental pathways involve activation
of secondary ossification centers. Since the epiphyses at these early
ages are composed of cartilage and therefore high in GAG content,
aberrant GAG accumulation in MPS VII is likely playing a role in
failed ossification. Indian Hedgehog signaling plays a crucial role in
regulating chondrocyte differentiation and is regulated in a highly
GAG-dependentmanner [3,4,5]. Our preliminary data showeddifferences
in Hedgehog pathway mRNA expression levels between heterozygote
and affected animals at both 9 and 14 days implicating this pathway in
disease etiology (figure). The results of this study lay the foundation for
future mechanistic investigations into bone disease in all MPS subtypes.
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